Inferra AIResearch Tools

Inferra AI / Company / ERAS

Erasca, Inc.

ERAS · Health Care

Last earnings Aug 11, 2026

AI analysis

Q2 2025 · reported Aug 12, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Accordingly, until such time as the Company can generate significant revenue from sales of its product candidates, if ever, the Company expects to finance its cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, or other similar arrangements.

Accounting estimates and management judgments reflected in the condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, stock-based compensation expense, the fair value of long-lived assets, the fair value of equity investments, and the incremental borrowing rate for determining the operating lease asset and liability.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Erasca, Inc. — Earnings release (2025-08-12)

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Accordingly, until such time as the Company can generate significant revenue from sales of its product candidates, if ever, the Company expects to finance its cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, or other similar arrangements.

SEC original ↗Erasca, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Accounting estimates and management judgments reflected in the condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, stock-based compensation expense, the fair value of long-lived assets, the fair value of equity investments, and the incremental borrowing rate for determining the operating lease asset and liability.

SEC original ↗Erasca, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to maturity.

SEC original ↗Erasca, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Interest and dividends on securities classified as available-for-sale are included in interest income.

SEC original ↗Erasca, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Cash equivalents consist of money market funds and commercial paper, short-term marketable securities consist of US treasury securities, US government agency securities, corporate debt securities, and commercial paper, and long-term marketable securities consist of US treasury securities and US government agency securities.

SEC original ↗Erasca, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Common stockholders are entitled to receive dividends, as may be declared by the Company s board of directors.

SEC original ↗Erasca, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Strategy & priorities

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended June 30, 2025.

SEC original ↗Erasca, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

SEC original ↗Erasca, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

(Erasca or the Company) is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

SEC original ↗Erasca, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The Company has assembled a RAS/MAPK pathway-focused pipeline comprising modality-agnostic programs aligned with its three therapeutic strategies of: (1) targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; (2) targeting RAS directly; and (3) targeting escape routes that emerge in response to treatment.

SEC original ↗Erasca, Inc. — 10-Q Quarterly report10-QAug 11, 2026

In March 2021, the Company established a wholly-owned subsidiary, Erasca Ventures, LLC (Erasca Ventures), to make investments in early-stage biotechnology companies that are aligned with the Company s mission and strategy.

SEC original ↗Erasca, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Risks & headwinds

Legal Proceedings 39 Item 1A.

SEC original ↗Erasca, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

30 documents

Earnings releases

9 documents

Presentations

0 documents

No presentations for Erasca, Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Erasca, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.